Companies /Healthcare

Crescent Biopharma, Inc.

NASDAQ: CBIO Biotechnology
$14.15
▼ $0.22 (−1.53%) today
Markets closed · 1:50pm ET

CBIO at a Glance

Valuation
Market cap
$591.3M
Profitability
Revenue (TTM)
$15.0M
EPS (TTM)
$-7.29
Price
52-week range
$9 – $27
Street target
$32.33

Headquartered in Waltham, MA Fiscal year ends December NASDAQ: CBIO crescentbiopharma.com

About Crescent Biopharma

Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage oncology biotechnology company developing therapies for solid tumors, both as single agents and in combination regimens. Its pipeline uses multiple modalities against established targets:
- CR-001: a PD-1 x VEGF bispecific antibody, in the global Phase 1/2 ASCEND trial as monotherapy and with standard-of-care chemotherapy.
- CR-002: a topoisomerase inhibitor antibody-drug conjugate (ADC) targeting PD-L1, in the global Phase 1/2 APOLLO trial.
- CR-003 (SKB105): an ITGB6-targeted topoisomerase inhibitor ADC, in-licensed from Kelun-Biotech for markets outside Greater China.

Through a strategic collaboration, Kelun-Biotech holds Greater China rights to CR-001 (SKB118). It is evaluating CR-001 in combination with its TROP2-directed ADC sacituzumab tirumotecan in multiple Phase 2 trials, and both companies may develop CR-001 in combination with their own ADC pipelines. Crescent currently generates license agreement revenue and funds operations mainly through equity financing, including a July 2026 public offering. Updated

CBIO Coverage

Frequently Asked Questions

What does Crescent Biopharma do?

Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage oncology biotechnology company developing therapies for solid tumors, both as single agents and in combination regimens.

What is the CBIO stock price target?

The Wall Street consensus 12-month price target for CBIO is $32.33.